JP2010527981A5 - - Google Patents

Download PDF

Info

Publication number
JP2010527981A5
JP2010527981A5 JP2010508909A JP2010508909A JP2010527981A5 JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5 JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010508909 A JP2010508909 A JP 2010508909A JP 2010527981 A5 JP2010527981 A5 JP 2010527981A5
Authority
JP
Japan
Prior art keywords
week
chk
administered
treatment
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010508909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/050372 external-priority patent/WO2008146035A1/en
Publication of JP2010527981A publication Critical patent/JP2010527981A/ja
Publication of JP2010527981A5 publication Critical patent/JP2010527981A5/ja
Pending legal-status Critical Current

Links

JP2010508909A 2007-05-25 2008-05-23 癌処置用のchk阻害剤およびparp阻害剤の組み合わせ剤 Pending JP2010527981A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
PCT/GB2008/050372 WO2008146035A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Publications (2)

Publication Number Publication Date
JP2010527981A JP2010527981A (ja) 2010-08-19
JP2010527981A5 true JP2010527981A5 (enExample) 2011-06-30

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508909A Pending JP2010527981A (ja) 2007-05-25 2008-05-23 癌処置用のchk阻害剤およびparp阻害剤の組み合わせ剤

Country Status (11)

Country Link
US (1) US20100249112A1 (enExample)
EP (1) EP2167086A1 (enExample)
JP (1) JP2010527981A (enExample)
KR (1) KR20100020981A (enExample)
CN (1) CN101743003A (enExample)
AU (1) AU2008256562A1 (enExample)
BR (1) BRPI0811059A2 (enExample)
CA (1) CA2687786A1 (enExample)
MX (1) MX2009012705A (enExample)
RU (1) RU2009147819A (enExample)
WO (1) WO2008146035A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
JP2013532683A (ja) 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ(adpリボース)ポリメラーゼ−1阻害剤としての、置換4−(4−フルオロ−3−(ピペラジン−1−カルボニル)ベンジル)フタラジン−1(2h)−オン誘導体
US20140044802A1 (en) * 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2938598T3 (en) 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
ES2879434T3 (es) 2015-07-23 2021-11-22 Inst Curie Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
KR102645511B1 (ko) * 2017-04-10 2024-03-08 시에라 온코로지 엘엘씨 종양 성장을 저해하는 CHK1(SRA737)/PARPi 조합 방법
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CN111936143A (zh) 2018-04-05 2020-11-13 诺维嘉研究公司 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Chk1抑制劑之合成方法
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004220321B2 (en) * 2003-03-12 2010-02-25 Kudos Pharmaceuticals Ltd Phthalazinone derivatives
TWI338000B (en) * 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
WO2005066163A2 (en) * 2004-01-05 2005-07-21 Astrazeneca Ab Thiophene derivatives as chk 1 inihibitors
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Similar Documents

Publication Publication Date Title
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2024133475A5 (enExample)
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
JP2013507415A5 (enExample)
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
FI2694072T4 (fi) Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
JP2014515373A5 (enExample)
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
CL2018001371A1 (es) Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807)
NZ714963A (en) Compositions and methods for treating anemia
JP2014528901A5 (enExample)
JP2012526850A5 (enExample)
JP2016529285A5 (enExample)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2016516773A5 (enExample)
EP4520398A3 (en) Treatment of prostate cancer
UA104148C2 (ru) [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
JP2020523354A5 (enExample)
JP2015535247A5 (enExample)
CL2024001530A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
JP2013544892A5 (enExample)
IL259512B1 (en) Combination for effective treatment of metastatic cancer in patients